Results 131 to 140 of about 59,706 (153)

ASSESSING THE ACTIVITY OF MYOPIC CHOROIDAL NEOVASCULARIZATION: Comparison Between Optical Coherence Tomography Angiography and Dye Angiography. [PDF]

Retina, 2020
Li S, Sun L, Zhao X, Huang S, Luo X, Zhang A, Chen C, Wang Z, Liu C, Ding X.   +9 more
europepmc   +1 more source

Infographic: Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. [PDF]

Eye (Lond)
Yusuf IH, Henein C, Sivaprasad S.
europepmc   +1 more source

Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes. [PDF]

BMC Ophthalmol
Kang MT, Wang N, Xu W, Yusufu M, Liu W, Tian J, Qi Y.   +6 more
europepmc   +1 more source

Hyperreflective Material in Optical Coherence Tomography Images of Eyes with Myopic Choroidal Neovascularization May Affect the Visual Outcome. [PDF]

J Clin Med, 2020
Mushiga Y, Minami S, Uchida A, Nagai N, Suzuki M, Kurihara T, Sonobe H, Ban N, Watanabe K, Shinoda H, Tsubota K, Ozawa Y.   +11 more
europepmc   +1 more source

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. [PDF]

PLoS One, 2020
Hamilton RD, Clemens A, Minnella AM, Lai TYY, Dai H, Sakamoto T, Gemmy Cheung CM, Ngah NF, Dunger-Baldauf C, Holz FG, LUMINOUS study group.   +10 more
europepmc   +1 more source

Ranibizumab for myopic choroidal neovascularization

Expert Opinion on Biological Therapy, 2020
Introduction: Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF ...
Danny Siu-Chun Ng, Nicholas S K Fung, Timothy Y Y Lai   +2 more
exaly   +2 more sources

Three cases of macular retinal detachment exacerbated during follow-up with myopic foveoschisis around myopic choroidal neovascularization [PDF]

American Journal of Ophthalmology Case Reports, 2023
Shigeru Sato, Yoko Fukushima, Kohji Nishida   +2 more
exaly   +2 more sources

Pharmacotherapy of Myopic Choroidal Neovascularization

Current Pharmaceutical Design, 2019
Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals.
Harry W Flynn, Hacer Işıldak
exaly   +2 more sources

Pathogenesis of myopic choroidal neovascularization: A systematic review and meta-analysis

Survey of Ophthalmology, 2023
Myopic choroidal neovascularization (CNV) is a vision-threatening complication of high myopia. Here, we systematically review cohort, case-control, and cross-sectional studies in PubMed, Embase, and Web of Science, and summarize the associated factors of
Jason C S Yam, Xiujuan Zhang, Chi Pui Pang   +2 more
exaly   +2 more sources

Intravitreal Bevacizumab (Avastin) as Primary Treatment for Myopic Choroidal Neovascularization

European Journal of Ophthalmology, 2007
Purpose To evaluate the short-term efficacy and safety of intravitreal bevacizumab in myopic choroidal neovascularization (mCNV). Methods In this noncomparative, consecutive, interventional case series, 12 eyes of 11 patients with mCNV without any ...
Pradeep Venkatesh
exaly   +2 more sources